|
Clinical Trials for Treatment of Idiopathic Hypereosinophilic Syndrome
At M. D. Anderson Cancer Center, we are committed to establishing state of the art treatment for idiopathic hypereosinophilic syndrome (HES).

|

|
Dr. Cortes of the Department of Leukemia at an ongoing study for patients with idiopathic HES using imatinib mesylate (Gleevec®). More information.
Contact Information:
- Jorge E. Cortes-Franco, M.D., Principal Investigator, at (713) 794-5783
- Mary Beth Rios, RN, protocol manager, at (713) 792-6408 or (713) 404-3367 (pager)
|

Further, we have two clinical studies for available for those HES patients who do not achieve a complete remission with the Gleevec study.
|

|
Michael Andreeff, M.D., Ph.D., of the Section of Molecular Hematology is accruing patients for treatment of HES with 2-chlorodeoxyadenosine (2-CdA) and Ara-C (Cytarabine). More information.
Contact Information:
-
Michael Andreeff, M.D., Ph.D., Principal Investigator, at (713) 792-7260
-
Ellen Jackson, RN, BSN, protocol manager, at (713) 745-2927 or (713) 404-6479 (pager) |
|

|
Dr. Naoto Ueno of the Department of Blood and Marrow has a study open for patients with HES using mini-allogeneic transplantation (non-myeloablative). More information.
Contact Information:
-
Naoto T. Ueno, M.D., Ph.D., Principal Investigator, at (713) 792-8754
-
Eugene Sturm, RN, protocol manager, at (713) 792-7351 or (713) 404-0435 (pager) |
We anticipate to establish a treatment standard for patients with idiopathic HES, and, minimally, to improve outcomes for this patient population. The protocols are open and ready for patient accrual.
|
|